JBM (Healthcare) Limited (2161 HK) has scheduled a board meeting on 17 November 2025 to consider and approve the interim results for the six months ended 30 September 2025. Plans for an interim dividend, if any, will be reviewed, alongside other business matters. The announcement was issued on 5 November 2025.
The Board is chaired by an executive director and includes additional executive, non-executive, and independent non-executive directors. The interim results and any potential recommendation for a dividend will be published following the meeting, in accordance with regulatory disclosure requirements.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.